Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort.

Alter P, Mayerhofer BA, Kahnert K, Watz H, Waschki B, Andreas S, Biertz F, Bals R, Vogelmeier CF, Jörres RA.

Int J Chron Obstruct Pulmon Dis. 2019 Sep 20;14:2163-2172. doi: 10.2147/COPD.S209343. eCollection 2019.

2.

Consequences of chronic kidney disease in chronic obstructive pulmonary disease.

Trudzinski FC, Alqudrah M, Omlor A, Zewinger S, Fliser D, Speer T, Seiler F, Biertz F, Koch A, Vogelmeier C, Welte T, Watz H, Waschki B, Fähndrich S, Jörres R, Bals R; German COSYCONET consortium.

Respir Res. 2019 Jul 12;20(1):151. doi: 10.1186/s12931-019-1107-x.

3.

Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis.

Fermont JM, Masconi KL, Jensen MT, Ferrari R, Di Lorenzo VAP, Marott JM, Schuetz P, Watz H, Waschki B, Müllerova H, Polkey MI, Wilkinson IB, Wood AM.

Thorax. 2019 May;74(5):439-446. doi: 10.1136/thoraxjnl-2018-211855. Epub 2019 Jan 7.

4.

Right Ventricular Index for Risk Stratification of Patients with Pulmonary Arterial Hypertension.

Sinning C, Harbaum L, Schrage B, Rübsamen N, Magnussen C, Waschki B, Kleemann WH, Baaske KM, Kögler M, Ojeda F, Fischer C, Benjamin N, Westermann D, Zengin E, Schäfer U, Egenlauf B, Klose HF, Blankenberg S, Grünig E.

Respiration. 2018;96(3):249-258. doi: 10.1159/000489231. Epub 2018 Jul 12.

PMID:
30001556
5.

Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling.

Alter P, Watz H, Kahnert K, Pfeifer M, Randerath WJ, Andreas S, Waschki B, Kleibrink BE, Welte T, Bals R, Schulz H, Biertz F, Young D, Vogelmeier CF, Jörres RA.

Respir Med. 2018 Apr;137:14-22. doi: 10.1016/j.rmed.2018.02.011. Epub 2018 Feb 19.

PMID:
29605197
6.

Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils.

Pedersen F, Waschki B, Marwitz S, Goldmann T, Kirsten A, Malmgren A, Rabe KF, Uddin M, Watz H.

Eur Respir J. 2018 Apr 12;51(4). pii: 1700970. doi: 10.1183/13993003.00970-2017. Print 2018 Apr. No abstract available.

7.

Physical Activity and Fatigue in Patients with Sarcoidosis.

Bahmer T, Watz H, Develaska M, Waschki B, Rabe KF, Magnussen H, Kirsten D, Kirsten AM.

Respiration. 2018;95(1):18-26. doi: 10.1159/000481827. Epub 2017 Nov 9.

8.

Physical activity patterns and clusters in 1001 patients with COPD.

Mesquita R, Spina G, Pitta F, Donaire-Gonzalez D, Deering BM, Patel MS, Mitchell KE, Alison J, van Gestel AJ, Zogg S, Gagnon P, Abascal-Bolado B, Vagaggini B, Garcia-Aymerich J, Jenkins SC, Romme EA, Kon SS, Albert PS, Waschki B, Shrikrishna D, Singh SJ, Hopkinson NS, Miedinger D, Benzo RP, Maltais F, Paggiaro P, McKeough ZJ, Polkey MI, Hill K, Man WD, Clarenbach CF, Hernandes NA, Savi D, Wootton S, Furlanetto KC, Cindy Ng LW, Vaes AW, Jenkins C, Eastwood PR, Jarreta D, Kirsten A, Brooks D, Hillman DR, Sant'Anna T, Meijer K, Dürr S, Rutten EP, Kohler M, Probst VS, Tal-Singer R, Gil EG, den Brinker AC, Leuppi JD, Calverley PM, Smeenk FW, Costello RW, Gramm M, Goldstein R, Groenen MT, Magnussen H, Wouters EF, ZuWallack RL, Amft O, Watz H, Spruit MA.

Chron Respir Dis. 2017 Aug;14(3):256-269. doi: 10.1177/1479972316687207. Epub 2017 Feb 24.

9.

Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis.

Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, Gramm M, Hummler S, Brunnemer E, Kreuter M, Watz H.

BMC Pulm Med. 2017 Jul 25;17(1):104. doi: 10.1186/s12890-017-0444-0.

10.

Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.

Waschki B, Watz H, Holz O, Magnussen H, Olejnicka B, Welte T, Rabe KF, Janciauskiene S.

Int J Chron Obstruct Pulmon Dis. 2017 Mar 22;12:981-987. doi: 10.2147/COPD.S128689. eCollection 2017.

11.

Analysis of nocturnal actigraphic sleep measures in patients with COPD and their association with daytime physical activity.

Spina G, Spruit MA, Alison J, Benzo RP, Calverley PMA, Clarenbach CF, Costello RW, Donaire-Gonzalez D, Dürr S, Garcia-Aymerich J, van Gestel AJR, Gramm M, Hernandes NA, Hill K, Hopkinson NS, Jarreta D, Kohler M, Kirsten AM, Leuppi JD, Magnussen H, Maltais F, Man WD, McKeough ZJ, Mesquita R, Miedinger D, Pitta F, Singh SJ, Smeenk FWJM, Tal-Singer R, Vagaggini B, Waschki B, Watz H, Wouters EFM, Zogg S, den Brinker AC.

Thorax. 2017 Aug;72(8):694-701. doi: 10.1136/thoraxjnl-2016-208900. Epub 2017 Jan 12.

12.

Physical activity, airway resistance and small airway dysfunction in severe asthma.

Bahmer T, Waschki B, Schatz F, Herzmann C, Zabel P, Kirsten AM, Rabe KF, Watz H; ERA-Study Group.

Eur Respir J. 2017 Jan 4;49(1). pii: 1601827. doi: 10.1183/13993003.01827-2016. Print 2017 Jan. No abstract available.

13.

Angiopoietin-like protein 4 and cardiovascular function in COPD.

Waschki B, Kirsten AM, Holz O, Meyer T, Lichtinghagen R, Rabe KF, Magnussen H, Welte T, Watz H, Janciauskiene S.

BMJ Open Respir Res. 2016 Oct 31;3(1):e000161. eCollection 2016.

14.

Clinical Correlates of Reduced Physical Activity in Idiopathic Pulmonary Fibrosis.

Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, Gramm M, Hummler S, Brunnemer E, Kreuter M, Watz H.

Respiration. 2016;91(6):497-502. doi: 10.1159/000446607. Epub 2016 Jun 1.

15.

Reduced physical activity in lymphangioleiomyomatosis compared with COPD and healthy controls: disease-specific impact and clinical correlates.

Bahmer T, Watz H, Waschki B, Gramm M, Magnussen H, Rabe KF, Wirtz H, Kirsten D, Kirsten A.

Thorax. 2016 Jul;71(7):662-3. doi: 10.1136/thoraxjnl-2015-207852. Epub 2016 Mar 11.

PMID:
26968971
16.

Handgrip weakness and mortality risk in COPD: a multicentre analysis.

Burtin C, Ter Riet G, Puhan MA, Waschki B, Garcia-Aymerich J, Pinto-Plata V, Celli B, Watz H, Spruit MA.

Thorax. 2016 Jan;71(1):86-7. doi: 10.1136/thoraxjnl-2015-207451. Epub 2015 Oct 29. No abstract available.

PMID:
26514408
17.

Neutrophil extracellular trap formation and extracellular DNA in sputum of stable COPD patients.

Pedersen F, Marwitz S, Holz O, Kirsten A, Bahmer T, Waschki B, Magnussen H, Rabe KF, Goldmann T, Uddin M, Watz H.

Respir Med. 2015 Oct;109(10):1360-2. doi: 10.1016/j.rmed.2015.08.008. Epub 2015 Aug 22.

18.

Disease Progression and Changes in Physical Activity in Patients with Chronic Obstructive Pulmonary Disease.

Waschki B, Kirsten AM, Holz O, Mueller KC, Schaper M, Sack AL, Meyer T, Rabe KF, Magnussen H, Watz H.

Am J Respir Crit Care Med. 2015 Aug 1;192(3):295-306. doi: 10.1164/rccm.201501-0081OC.

PMID:
26020495
19.

An official European Respiratory Society statement on physical activity in COPD.

Watz H, Pitta F, Rochester CL, Garcia-Aymerich J, ZuWallack R, Troosters T, Vaes AW, Puhan MA, Jehn M, Polkey MI, Vogiatzis I, Clini EM, Toth M, Gimeno-Santos E, Waschki B, Esteban C, Hayot M, Casaburi R, Porszasz J, McAuley E, Singh SJ, Langer D, Wouters EF, Magnussen H, Spruit MA.

Eur Respir J. 2014 Dec;44(6):1521-37. doi: 10.1183/09031936.00046814. Epub 2014 Oct 30.

20.

Potential prognostic value of biomarkers in lavage, sputum and serum in a five year clinical follow-up of smokers with and without COPD.

Holz O, Waschki B, Roepcke S, Watz H, Lauer G, Faulenbach C, Hohlfeld JM.

BMC Pulm Med. 2014 Mar 1;14:30. doi: 10.1186/1471-2466-14-30.

21.

Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity.

Cockayne DA, Cheng DT, Waschki B, Sridhar S, Ravindran P, Hilton H, Kourteva G, Bitter H, Pillai SG, Visvanathan S, Müller KC, Holz O, Magnussen H, Watz H, Fine JS.

PLoS One. 2012;7(6):e38629. doi: 10.1371/journal.pone.0038629. Epub 2012 Jun 12.

22.

Hyponatremia as prognostic factor in small cell lung cancer--a retrospective single institution analysis.

Hermes A, Waschki B, Reck M.

Respir Med. 2012 Jun;106(6):900-4. doi: 10.1016/j.rmed.2012.02.010. Epub 2012 Mar 8.

23.

Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study.

Waschki B, Spruit MA, Watz H, Albert PS, Shrikrishna D, Groenen M, Smith C, Man WD, Tal-Singer R, Edwards LD, Calverley PM, Magnussen H, Polkey MI, Wouters EF.

Respir Med. 2012 Apr;106(4):522-30. doi: 10.1016/j.rmed.2011.10.022. Epub 2011 Nov 25.

24.

Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study.

Waschki B, Kirsten A, Holz O, Müller KC, Meyer T, Watz H, Magnussen H.

Chest. 2011 Aug;140(2):331-342. doi: 10.1378/chest.10-2521. Epub 2011 Jan 27.

PMID:
21273294
25.

[Analysis of treatment outcomes in two patient cohorts (2004-2005 and 2007-2008) with limited and extensive disease small-cell lung cancer].

Hermes A, Waschki B, Gatzemeier U, Reck M.

Pneumologie. 2011 Apr;65(4):203-7. doi: 10.1055/s-0030-1256122. Epub 2011 Jan 25. German.

26.

Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer - a retrospective single institution analysis.

Hermes A, Gatzemeier U, Waschki B, Reck M.

Respir Med. 2010 Dec;104(12):1937-42. doi: 10.1016/j.rmed.2010.07.013. Epub 2010 Aug 16.

27.

Characteristics, treatment patterns and outcomes of patients with small cell lung cancer--a retrospective single institution analysis.

Hermes A, Waschki B, Gatzemeier U, Reck M.

Lung Cancer. 2011 Mar;71(3):363-6. doi: 10.1016/j.lungcan.2010.06.003. Epub 2010 Jul 8.

PMID:
20619477
28.

Emphysema, airflow obstruction, and left ventricular filling.

Watz H, Waschki B, Magnussen H.

N Engl J Med. 2010 Apr 29;362(17):1638-9; author reply 1640-1. doi: 10.1056/NEJMc1002018. No abstract available.

PMID:
20427814
29.

Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation.

Watz H, Waschki B, Meyer T, Kretschmar G, Kirsten A, Claussen M, Magnussen H.

Chest. 2010 Jul;138(1):32-8. doi: 10.1378/chest.09-2810. Epub 2010 Feb 26.

PMID:
20190002
30.

The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity.

Watz H, Waschki B, Kirsten A, Müller KC, Kretschmar G, Meyer T, Holz O, Magnussen H.

Chest. 2009 Oct;136(4):1039-1046. doi: 10.1378/chest.09-0393. Epub 2009 Jun 19.

PMID:
19542257
31.

[Measurement of physical activity in patients with chronic obstructive pulmonary disease].

Magnussen H, Waschki B, Watz H.

Med Klin (Munich). 2009 Apr 15;104(4):303-8. doi: 10.1007/s00063-009-1052-4. Review. German.

PMID:
19399389
32.

Physical activity in patients with COPD.

Watz H, Waschki B, Meyer T, Magnussen H.

Eur Respir J. 2009 Feb;33(2):262-72. doi: 10.1183/09031936.00024608. Epub 2008 Nov 14. Erratum in: Eur Respir J. 2010 Aug;36(2):462.

33.

[Heart failure in chronic obstructive pulmonary disease (COPD)].

Watz H, Waschki B, Kirsten AM, Claussen M, Magnussen H.

Dtsch Med Wochenschr. 2008 Apr;133(14):717-9. doi: 10.1055/s-2008-1067313. Review. German.

PMID:
18363191
34.

Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study.

Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H.

Am J Respir Crit Care Med. 2008 Apr 1;177(7):743-51. Epub 2007 Nov 29.

PMID:
18048807

Supplemental Content

Loading ...
Support Center